Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

被引：0
|
作者：
Leslie, K. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sill, M. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Darcy, K. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Baron, A. T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wilken, J. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Godwin, A. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Cook, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, J. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Maihle, N. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
[2] Univ Iowa, Albuquerque, NM USA
[3] Gynecol Oncol Grp, Stat Off, Buffalo, NY USA
[4] Univ Kentucky, Lexington, KY USA
[5] Yale Univ, New Haven, CT USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Indiana Univ, Bloomington, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16542
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
    Leslie, Kimberly K.
    Sill, Michael W.
    Lankes, Heather A.
    Fischer, Edgar G.
    Godwin, Andrew K.
    Gray, Heidi
    Schilder, Russell J.
    Walker, Joan L.
    Tewari, Krishnansu
    Hanjani, Parviz
    Abulafia, Ovadia
    Rose, Peter G.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (02) : 345 - 350
  • [2] A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study
    Leslie, Kimberly K.
    Sill, Michael W.
    Fischer, Edgar
    Darcy, Kathleen M.
    Mannel, Robert S.
    Tewari, Krishnansu S.
    Hanjani, Parviz
    Wilken, Jason A.
    Baron, Andre T.
    Godwin, Andrew K.
    Schilder, Russell J.
    Singh, Meenakshi
    Maihle, Nita J.
    GYNECOLOGIC ONCOLOGY, 2013, 129 (03) : 486 - 494
  • [3] Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
    Aghajanian, Carol
    Sill, Michael W.
    Darcy, Kathleen M.
    Greer, Benjamin
    McMeekin, D. Scott
    Rose, Peter G.
    Rotmensch, Jacob
    Barnes, Mack N.
    Hanjani, Parviz
    Leslie, Kimberly K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2259 - 2265
  • [4] Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study
    Covens, A
    Brunetto, VL
    Markman, M
    Orr, JW
    Lentz, SS
    Benda, J
    GYNECOLOGIC ONCOLOGY, 2003, 89 (03) : 470 - 474
  • [5] Prognostic value of serum sEGFR and EGFR mutations in a phase II trial of gefitinib (Iressa®, ZD1839) in women with endometrial cancer
    Leslie, Kimberly
    Sill, Michael
    Darcy, Kathleen
    Baron, Andre
    Wilken, Jason
    Godwin, Andrew
    Cook, Linda
    Schilder, Russell
    Schilder, Jeanne
    Maihle, Nita
    CANCER RESEARCH, 2009, 69
  • [6] Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
    Han, Ernest S.
    Burger, Robert A.
    Darcy, Kathleen M.
    Sill, Michael W.
    Randall, Leslie M.
    Chase, Dana
    Parmakhtiar, Basmina
    Monk, Bradley J.
    Greer, Benjamin E.
    Connelly, Patrick
    DeGeest, Koen
    Fruehauf, John P.
    GYNECOLOGIC ONCOLOGY, 2010, 119 (03) : 484 - 490
  • [7] A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A gynecologic oncology group study
    Rose, PG
    Brunetto, VL
    VanLe, L
    Bell, J
    Walker, JL
    Lee, RB
    GYNECOLOGIC ONCOLOGY, 2000, 78 (02) : 212 - 216
  • [8] Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: A gynecologic oncology group study
    Plaxe, SC
    Blessing, JA
    Husseinzadeh, N
    Webster, KD
    Rader, JS
    Dunton, CJ
    GYNECOLOGIC ONCOLOGY, 2002, 84 (02) : 241 - 244
  • [9] A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
    Coleman, Robert L.
    Sill, Michael W.
    Lankes, Heather A.
    Fader, Amanda Nickles
    Finkler, Neil J.
    Hoffman, James S.
    Rose, Peter G.
    Sutton, Gregory P.
    Drescher, Charles W.
    McMeekin, D. Scott
    Hu, Wei
    Deavers, Michael
    Godwin, Andrew K.
    Alpaugh, R. Katherine
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 538 - 543
  • [10] A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study
    Miller, DS
    Blessing, JA
    Lentz, SS
    Waggoner, SE
    GYNECOLOGIC ONCOLOGY, 2002, 87 (03) : 247 - 251
12345